PMC:7283670 / 61047-62249 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T220","span":{"begin":291,"end":296},"obj":"Body_part"},{"id":"T221","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A220","pred":"fma_id","subj":"T220","obj":"http://purl.org/sig/ont/fma/fma49184"},{"id":"A221","pred":"fma_id","subj":"T221","obj":"http://purl.org/sig/ont/fma/fma49184"}],"text":"Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T142","span":{"begin":291,"end":296},"obj":"Body_part"},{"id":"T143","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A142","pred":"uberon_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/UBERON_0000165"},{"id":"A143","pred":"uberon_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/UBERON_0000165"}],"text":"Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020"}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T361","span":{"begin":99,"end":107},"obj":"Disease"},{"id":"T362","span":{"begin":177,"end":185},"obj":"Disease"}],"attributes":[{"id":"A361","pred":"mondo_id","subj":"T361","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A362","pred":"mondo_id","subj":"T362","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020"}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T571","span":{"begin":291,"end":296},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T572","span":{"begin":324,"end":330},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T573","span":{"begin":382,"end":387},"obj":"http://www.ebi.ac.uk/efo/EFO_0000825"},{"id":"T574","span":{"begin":526,"end":530},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T575","span":{"begin":543,"end":545},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T576","span":{"begin":589,"end":593},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T577","span":{"begin":606,"end":608},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T578","span":{"begin":1115,"end":1119},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"}],"text":"Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020"}

LitCovid-PD-CHEBI

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T633","span":{"begin":0,"end":323},"obj":"Sentence"},{"id":"T634","span":{"begin":324,"end":414},"obj":"Sentence"},{"id":"T635","span":{"begin":415,"end":546},"obj":"Sentence"},{"id":"T636","span":{"begin":547,"end":1202},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020"}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"1887","span":{"begin":59,"end":67},"obj":"Species"},{"id":"2055","span":{"begin":14,"end":33},"obj":"Chemical"},{"id":"2056","span":{"begin":116,"end":135},"obj":"Chemical"},{"id":"2057","span":{"begin":244,"end":263},"obj":"Chemical"},{"id":"2058","span":{"begin":444,"end":463},"obj":"Chemical"},{"id":"2059","span":{"begin":963,"end":982},"obj":"Chemical"},{"id":"2060","span":{"begin":1065,"end":1084},"obj":"Chemical"},{"id":"2121","span":{"begin":78,"end":97},"obj":"Disease"},{"id":"2122","span":{"begin":99,"end":107},"obj":"Disease"},{"id":"2123","span":{"begin":177,"end":185},"obj":"Disease"},{"id":"2124","span":{"begin":880,"end":885},"obj":"Disease"}],"attributes":[{"id":"A1887","pred":"tao:has_database_id","subj":"1887","obj":"Tax:9606"},{"id":"A2055","pred":"tao:has_database_id","subj":"2055","obj":"MESH:C558899"},{"id":"A2056","pred":"tao:has_database_id","subj":"2056","obj":"MESH:C558899"},{"id":"A2057","pred":"tao:has_database_id","subj":"2057","obj":"MESH:C558899"},{"id":"A2058","pred":"tao:has_database_id","subj":"2058","obj":"MESH:C558899"},{"id":"A2059","pred":"tao:has_database_id","subj":"2059","obj":"MESH:C558899"},{"id":"A2060","pred":"tao:has_database_id","subj":"2060","obj":"MESH:C558899"},{"id":"A2121","pred":"tao:has_database_id","subj":"2121","obj":"MESH:D018352"},{"id":"A2122","pred":"tao:has_database_id","subj":"2122","obj":"MESH:C000657245"},{"id":"A2123","pred":"tao:has_database_id","subj":"2123","obj":"MESH:C000657245"},{"id":"A2124","pred":"tao:has_database_id","subj":"2124","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days\nActive comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days\nNo intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)\nSecondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020"}